FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIF

	OMB APPROVAL											
OMB Number: 3235-02												
l	Estimated average burden											
l	hours per response:	0.5										

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MCHUGH THOMAS S					2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC AVDL]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify				
C/O AVADEL PHARMACEUTICALS PLC				3. Date of Earliest Transaction (Month/Day/Year) 12/07/2021								Chief Financial Officer					
10 EARLSFORT TERRACE					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable				
(Street) DUBLIN	12 L2	2	D02 T380									Line	X Form filed by One Reporting Person Form filed by More than One Reporting				
(City)	(S	tate)	(Zip)										Person				
		Ta	ble I - Non-	-Deriva	tive S	ecurities	s Acc	quired,	Dis	posed o	f, or Be	neficiall	y Owned				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da				Execution Date,		Transaction Disposed Of (D Code (Instr. 5)			es Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amoun Securities Beneficia Owned Fo Reported	s Fo lly (D) ollowing (I)	rm: Direct or Indirect (Instr. 4)	. Nature of ndirect Beneficial Ownership			
					Code	v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)		(Instr. 4)				
			Table II - D			curities <i>i</i>							Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Yo	Code (Instr.				6. Date Exercisable Expiration Date (Month/Day/Year)		•	of Securities		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)		Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)			
Stock Option (Right to Buy)	\$8.2	12/07/2021		A		150,000		(1)	1	12/07/2031	ADSs ⁽²⁾	150,000	\$0	150,000	D		

Explanation of Responses:

- $1.\ Options\ become\ exercisable\ as\ to\ 37{,}500\ ADSs\ on\ each\ of\ the\ first\ four\ anniversaries\ after\ the\ 12/07/2021\ grant\ date.$
- 2. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

/s/ Jerad Seurer, as Attorney-in-12/09/2021 **Fact**

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.